Recognizing that the RANKL/RANK pathway has a multifactorial effect in the immune system and might be modulated in several ways, the antitumor immunity led to evaluating the potential role of RANKL inhibitors in improving the efficacy of ICIs in the treatment of cancer [81,82]. The gene discussed is TNFRSF11A; the disease is cancer.